Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Anti-HIV small-molecule binding in the peptide subpocket of the CXCR4:CVX15 crystal structure.

Cox BD, Prosser AR, Katzman BM, Alcaraz AA, Liotta DC, Wilson LJ, Snyder JP.

Chembiochem. 2014 Jul 21;15(11):1614-20. doi: 10.1002/cbic.201402056. Epub 2014 Jul 2.

PMID:
24990206
2.

Hologram quantitative structure activity relationship, docking, and molecular dynamics studies of inhibitors for CXCR4.

Zhang C, Du C, Feng Z, Zhu J, Li Y.

Chem Biol Drug Des. 2015 Feb;85(2):119-36. doi: 10.1111/cbdd.12377. Epub 2014 Jul 10.

PMID:
24923360
3.

Progress toward rationally designed small-molecule peptide and peptidomimetic CXCR4 antagonists.

Våbenø J, Haug BE, Rosenkilde MM.

Future Med Chem. 2015;7(10):1261-83. doi: 10.4155/fmc.15.64. Review.

PMID:
26144264
4.

Insights into the mechanism of inhibition of CXCR4: identification of Piperidinylethanamine analogs as anti-HIV-1 inhibitors.

Das D, Maeda K, Hayashi Y, Gavande N, Desai DV, Chang SB, Ghosh AK, Mitsuya H.

Antimicrob Agents Chemother. 2015 Apr;59(4):1895-904. doi: 10.1128/AAC.04654-14. Epub 2015 Jan 12.

5.

Impact of the CXCR4 structure on docking-based virtual screening of HIV entry inhibitors.

Planesas JM, Pérez-Nueno VI, Borrell JI, Teixidó J.

J Mol Graph Model. 2012 Sep;38:123-36. doi: 10.1016/j.jmgm.2012.06.010. Epub 2012 Jul 3.

PMID:
23079643
6.

Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists.

Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R, Brooun A, Wells P, Bi FC, Hamel DJ, Kuhn P, Handel TM, Cherezov V, Stevens RC.

Science. 2010 Nov 19;330(6007):1066-71. doi: 10.1126/science.1194396. Epub 2010 Oct 7.

7.

Computational analysis of the structural mechanism of inhibition of chemokine receptor CXCR4 by small molecule antagonists.

Kawatkar SP, Yan M, Gevariya H, Lim MY, Eisold S, Zhu X, Huang Z, An J.

Exp Biol Med (Maywood). 2011 Jul;236(7):844-50. doi: 10.1258/ebm.2011.010345. Epub 2011 Jun 22.

8.

Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4-FC131 interactions.

Yoshikawa Y, Kobayashi K, Oishi S, Fujii N, Furuya T.

Bioorg Med Chem Lett. 2012 Mar 15;22(6):2146-50. doi: 10.1016/j.bmcl.2012.01.134. Epub 2012 Feb 8.

PMID:
22365757
9.

Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors.

Wong RS, Bodart V, Metz M, Labrecque J, Bridger G, Fricker SP.

Mol Pharmacol. 2008 Dec;74(6):1485-95. doi: 10.1124/mol.108.049775. Epub 2008 Sep 2.

10.

Studying the binding interactions of allosteric agonists and antagonists of the CXCR4 receptor.

Planesas JM, Pérez-Nueno VI, Borrell JI, Teixidó J.

J Mol Graph Model. 2015 Jul;60:1-14. doi: 10.1016/j.jmgm.2015.05.004. Epub 2015 May 30.

PMID:
26080355
11.

Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.

Skerlj RT, Bridger GJ, Kaller A, McEachern EJ, Crawford JB, Zhou Y, Atsma B, Langille J, Nan S, Veale D, Wilson T, Harwig C, Hatse S, Princen K, De Clercq E, Schols D.

J Med Chem. 2010 Apr 22;53(8):3376-88. doi: 10.1021/jm100073m.

PMID:
20297846
12.

The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor.

Mosi RM, Anastassova V, Cox J, Darkes MC, Idzan SR, Labrecque J, Lau G, Nelson KL, Patel K, Santucci Z, Wong RS, Skerlj RT, Bridger GJ, Huskens D, Schols D, Fricker SP.

Biochem Pharmacol. 2012 Feb 15;83(4):472-9. doi: 10.1016/j.bcp.2011.11.020. Epub 2011 Nov 28.

PMID:
22146583
13.

Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs.

Seibert C, Sakmar TP.

Curr Pharm Des. 2004;10(17):2041-62. Review.

PMID:
15279544
14.

Peptide-lead CXCR4 antagonists with high anti-HIV activity.

Fujii N, Tamamura H.

Curr Opin Investig Drugs. 2001 Sep;2(9):1198-202. Review.

PMID:
11717804
15.

[Development of selective antagonists against an HIV second receptor].

Tamamura H.

Yakugaku Zasshi. 2001 Nov;121(11):781-92. Review. Japanese.

16.

Oxovanadium(IV) cyclam and bicyclam complexes: potential CXCR4 receptor antagonists.

Ross A, Soares DC, Covelli D, Pannecouque C, Budd L, Collins A, Robertson N, Parsons S, De Clercq E, Kennepohl P, Sadler PJ.

Inorg Chem. 2010 Feb 1;49(3):1122-32. doi: 10.1021/ic9020614.

17.

Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5).

Garcia-Perez J, Rueda P, Alcami J, Rognan D, Arenzana-Seisdedos F, Lagane B, Kellenberger E.

J Biol Chem. 2011 Sep 23;286(38):33409-21. doi: 10.1074/jbc.M111.279596. Epub 2011 Jul 20.

18.

Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor.

Rosenkilde MM, Gerlach LO, Jakobsen JS, Skerlj RT, Bridger GJ, Schwartz TW.

J Biol Chem. 2004 Jan 23;279(4):3033-41. Epub 2003 Oct 28.

19.

A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.

Tamamura H, Xu Y, Hattori T, Zhang X, Arakaki R, Kanbara K, Omagari A, Otaka A, Ibuka T, Yamamoto N, Nakashima H, Fujii N.

Biochem Biophys Res Commun. 1998 Dec 30;253(3):877-82.

PMID:
9918823
20.

Computer-based design of novel HIV-1 entry inhibitors: neomycin conjugated to arginine peptides at two specific sites.

Berchanski A, Lapidot A.

J Mol Model. 2009 Mar;15(3):281-94. doi: 10.1007/s00894-008-0401-1. Epub 2008 Dec 5.

PMID:
19057930
Items per page

Supplemental Content

Write to the Help Desk